These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12019103)

  • 41. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.
    Veziris N; Ibrahim M; Lounis N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
    Am J Respir Crit Care Med; 2009 Jan; 179(1):75-9. PubMed ID: 18948422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.
    Cynamon MH; Zhang Y; Harpster T; Cheng S; DeStefano MS
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2922-4. PubMed ID: 10582883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense.
    Choi GE; Min KN; Won CJ; Jeon K; Shin SJ; Koh WJ
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3549-55. PubMed ID: 22564831
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.
    Pienaar E; Sarathy J; Prideaux B; Dietzold J; Dartois V; Kirschner DE; Linderman JJ
    PLoS Comput Biol; 2017 Aug; 13(8):e1005650. PubMed ID: 28817561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice.
    Grosset J; Lounis N; Truffot-Pernot C; O'Brien RJ; Raviglione MC; Ji B
    Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1436-40. PubMed ID: 9603120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.
    Capitano B; Mattoes HM; Shore E; O'Brien A; Braman S; Sutherland C; Nicolau DP
    Chest; 2004 Mar; 125(3):965-73. PubMed ID: 15006955
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.
    Veziris N; Ibrahim M; Lounis N; Andries K; Jarlier V
    PLoS One; 2011 Mar; 6(3):e17556. PubMed ID: 21408613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis.
    Dietze R; Teixeira L; Rocha LM; Palaci M; Johnson JL; Wells C; Rose L; Eisenach K; Ellner JJ
    Antimicrob Agents Chemother; 2001 Jul; 45(7):1972-6. PubMed ID: 11408210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fully weekly antituberculosis regimen: a proof-of-concept study.
    Kort F; Fournier Le Ray L; Chauffour A; Jarlier V; Lounis N; Andries K; Aubry A; Guglielmetti L; Veziris N
    Eur Respir J; 2020 Sep; 56(3):. PubMed ID: 32430417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activity of Moxifloxacin against
    Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693
    [TBL] [Abstract][Full Text] [Related]  

  • 55. P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
    Brillault J; De Castro WV; Harnois T; Kitzis A; Olivier JC; Couet W
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1457-62. PubMed ID: 19188390
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
    Cremades R; Rodríguez JC; García-Pachón E; Galiana A; Ruiz-García M; López P; Royo G
    J Antimicrob Chemother; 2011 Oct; 66(10):2281-3. PubMed ID: 21733966
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice.
    Consigny S; Bentoucha A; Bonnafous P; Grosset J; Ji B
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2919-21. PubMed ID: 10991891
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors.
    Reuveni D; Halperin D; Fabian I; Tsarfaty G; Askenasy N; Shalit I
    Biochem Pharmacol; 2010 Apr; 79(8):1100-7. PubMed ID: 20025849
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
    Bermudez LE; Inderlied CB; Kolonoski P; Petrofsky M; Aralar P; Wu M; Young LS
    Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model.
    Gillespie SH; Morrissey I; Everett D
    J Med Microbiol; 2001 Jun; 50(6):565-570. PubMed ID: 11393294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.